Transforming Molecular Diagnostics through NanoTechnology

Biotechnology startup Altratech Ltd was founded with the vision to transform molecular diagnostics through nanotechnology.

Wehave developed and patented a novel technology for molecular testing of viruses and pathogens in non-clinical environments.

Thisall-synthetic novel assay can detect and quantify DNA, RNA, Antibody, and Antigen molecular targets, from blood or saliva samples, in20 mins, without any need of centrifuges or pipettes.

This will enable market-disrupting products that have the simplicity of apregnancy test and the performance of a laboratory PCR test.All molecular diagnostic systems today require biological amplification, i.e., polymerase chain reaction (PCR), Loop-mediatedpolymerase amplification (LAMP), or similar.

This takes time, and requires trained personnel, refrigeration for enzymes, and specialisedequipment for heating/cooling and optical detection.

It is because of these requirements that there is no solution on the markettoday for the non-clinical detection, monitoring, and management of viral infections such as HIV, Hepatitis, Influenza, Malaria,Meningitis, Shingles, Dengue Fever, HPV, EBV-related cancers, and many more.Our solution is a molecular detection process that eliminates the requirement for biological amplification and optical detection.

Wehave invented and patented the key breakthrough of detecting and quantifying genetic material, viruses, and pathogens usingalmost instant electronic signal amplification, with semiconductor sensing and digital readout.The Value Proposition to our target customers, who will be the worlds leading diagnostic companies, is the ability to licence a novelpatent protected product, with a wider range of market applications compared to their current diagnostic products.

This willfacilitate their entry into new markets and increase gross margins in existing markets.This innovation will impact the 48B Diagnostics industry.